MoonLake Immunotherapeutics
$ 13.83
-0.29%
26 Dec - close price
- Market Cap 979,820,000 USD
- Current Price $ 13.83
- High / Low $ 13.99 / 13.51
- Stock P/E N/A
- Book Value 4.54
- EPS -3.33
- Next Earning Report 2026-02-26
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.31 %
- ROE -0.54 %
- 52 Week High 62.75
- 52 Week Low 5.95
About
None
Analyst Target Price
$14.61
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-05 | 2025-08-05 | 2025-05-05 | 2025-02-26 | 2024-11-12 | 2024-08-07 | 2024-05-07 | 2024-02-29 | 2023-11-14 | 2023-08-10 | 2023-05-12 | 2023-03-20 |
| Reported EPS | -1.1 | -0.87 | -0.63 | -0.72 | -0.56 | -0.39 | -0.22 | -0.12 | -0.18 | -0.23 | -0.23 | -0.31 |
| Estimated EPS | -0.8788 | -0.72 | -0.7355 | -0.5928 | -0.44 | -0.28 | -0.19 | -0.23 | -0.23 | -0.27 | -0.31 | -0.33 |
| Surprise | -0.2212 | -0.15 | 0.1055 | -0.1272 | -0.12 | -0.11 | -0.03 | 0.11 | 0.05 | 0.04 | 0.08 | 0.02 |
| Surprise Percentage | -25.1707% | -20.8333% | 14.344% | -21.4575% | -27.2727% | -39.2857% | -15.7895% | 47.8261% | 21.7391% | 14.8148% | 25.8065% | 6.0606% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-02-26 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | -0.9792 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: MLTX
2025-12-20 08:09:06
The Gross Law Firm is urging shareholders of MoonLake Immunotherapeutics (NASDAQ: MLTX) who incurred losses during the class period of March 10, 2024, to September 29, 2025, to join a class action lawsuit. The complaint alleges that the company made false or misleading statements regarding its sole drug candidate, SLK, particularly its purported superiority over BIMZELX. Shareholders have until December 15, 2025, to register as lead plaintiff.
2025-12-18 09:09:06
Bleichmar Fonti & Auld LLP has filed a securities class action lawsuit against MoonLake Immunotherapeutics (NASDAQ: MLTX) and its executives. The lawsuit alleges that MoonLake misled investors regarding the efficacy of its drug sonelokimab, leading to a significant stock price drop after disappointing Phase 3 trial results. Investors who purchased MoonLake common stock have until December 15, 2025, to seek appointment as lead plaintiff in the case.
2025-12-16 10:08:31
Levi & Korsinsky, LLP has filed a class action securities lawsuit against MoonLake Immunotherapeutics (NASDAQ:MLTX) on behalf of investors who suffered losses between March 10, 2024, and September 29, 2025. The lawsuit alleges that the company made false statements regarding its drug candidate, SLK, and its purported superiority to monoclonal antibodies. Shareholders affected are encouraged to contact Levi & Korsinsky for information on potential recovery.
2025-12-16 10:08:31
Levi & Korsinsky, LLP has filed a securities class action lawsuit against MoonLake Immunotherapeutics (MLTX) on behalf of investors who suffered losses between March 10, 2024, and September 29, 2025. The lawsuit alleges that MoonLake made false statements and concealed information regarding its drug candidate, SLK, specifically concerning its purported superiority over BIMZELX. Investors affected are encouraged to contact Levi & Korsinsky to explore potential recovery under federal securities laws before December 15, 2025.
2025-12-16 10:08:31
The Gross Law Firm is urging shareholders who lost money on MoonLake Immunotherapeutics (NASDAQ: MLTX) shares purchased between March 10, 2024, and September 29, 2025, to join a class action lawsuit. The lawsuit alleges that MoonLake Immunotherapeutics made misleading statements regarding its drug candidate SLK, specifically concerning its purported superiority over BIMZELX and its clinical efficacy. Shareholders have until December 15, 2025, to register as a lead plaintiff.
2025-12-16 10:08:31
The Portnoy Law Firm has announced a class action lawsuit on behalf of investors in MoonLake Immunotherapeutics, Inc. (NASDAQ: MLTX). The lawsuit alleges that MoonLake made misleading statements regarding its sole drug candidate, sonelokimab (SLK), developed for hidradenitis suppurativa (HS), particularly concerning its efficacy compared to a competing drug. Investors who purchased securities between March 10, 2024, and September 29, 2025, have until December 15, 2025, to file a lead plaintiff motion.
